TTF-1 and immune checkpoint therapy in non-small cell lung cancer
- PMID: 37057105
- PMCID: PMC10087989
- DOI: 10.21037/tlcr-23-101
TTF-1 and immune checkpoint therapy in non-small cell lung cancer
Keywords: Thyroid transcription factor-1 (TTF-1); immune checkpoint therapy; non-small cell lung cancer (NSCLC).
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-101/coif). MG reports patents licensed to Alterna Theraputics and honoraria from MJH Lifesciences and OMNI Health Media, all outside the scope of this publication. ELS has no conflicts of interest to declare.
Comment on
-
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215. doi: 10.21037/tlcr-22-393. Transl Lung Cancer Res. 2022. PMID: 36519019 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources